Applied Protocols with Leptin (116-130), Amide, Mouse in Obesity Research

Principle and Setup: Leveraging a Key Adipocyte-Derived Hormone Fragment

Leptin (116-130), amide, mouse, available from APExBIO, is a synthetically produced peptide fragment derived from the native mouse leptin sequence. Comprising the Ser-Cys-Ser-Leu-Pro-Gln-Thr-Ser-Gly-Leu-Gln-Lys-Pro-Glu-Ser-NH2 motif, this fragment retains the biological functionality necessary to interrogate pathways of energy homeostasis regulation and metabolic signaling. Unlike full-length leptin, the 116-130 amide form is highly soluble in DMSO (≥156 mg/mL) and water (≥24.15 mg/mL), facilitating rapid preparation for both in vitro and in vivo assays. Its stability profile—solid, desiccated storage at −20°C—ensures minimal degradation and batch-to-batch reliability when handled per product specifications.

Functionally, this peptide fragment mimics the effects of native leptin, notably in food intake suppression, body weight regulation, and modulation of immunometabolic cross-talk. Its defined sequence allows for precise mechanistic dissection of leptin signaling pathway perturbations in models of obesity, diabetes, and leptin resistance or deficiency. Importantly, the pleiotropic effects of leptin extend beyond metabolism, influencing angiogenesis, hematopoiesis, and immune cell dynamics, making the 116-130 fragment a versatile tool for researchers bridging metabolic and inflammatory disease models.

Step-by-Step Workflow: Maximizing Reproducibility in Obesity and Diabetes Research

To extract the full potential of Leptin (116-130), amide, mouse in translational research, a standardized experimental workflow is essential. The following protocol enhancements integrate insights from recent applications and established best practices:

Protocol Parameters

• Peptide Reconstitution: Dissolve at 1–5 mg/mL in sterile DMSO or water, ensuring complete solubilization via brief vortexing and gentle sonication for 5–10 minutes at room temperature (20–25°C).
• In Vitro Assays: Add to cell culture media at working concentrations of 0.1–10 μM, incubating for 12–48 hours to assess effects on adipocyte differentiation, glucose uptake, or inflammatory cytokine production.
• In Vivo Dosing: Administer intraperitoneally at 0.5–1 mg/kg body weight daily for 7–14 days in mouse models of diet-induced obesity or leptin deficiency, monitoring body weight and metabolic endpoints.

Critical quality control includes preparing solutions fresh before use, as prolonged storage (even at 4°C) can reduce activity. For co-administration or comparative studies, pair with metabolic or immunological readouts such as glucose tolerance tests, ELISA for leptin-responsive cytokines, or flow cytometric analysis of T lymphocyte populations.

Key Innovation from the Reference Study

A pivotal advance highlighted by the recent reference study is the strategic targeting of the SIRT6-AMPK pathway to modulate inflammatory and metabolic remodeling in disease states, notably atrial fibrillation (AF) induced by angiotensin II. The use of SIRT6 overexpression and knockdown in murine models, alongside pharmacological agents, underscores the translational value of dissecting hormone fragment signaling in both metabolic and cardiovascular contexts.

For researchers employing Leptin (116-130), amide, mouse, this insight translates into practical assay choices: incorporating readouts of SIRT6-AMPK pathway activation (e.g., AMPK phosphorylation, SIRT6 expression by Western blot) can directly link leptin fragment effects to broader metabolic and inflammatory remodeling. This approach enables the exploration of novel anti-fibrotic or anti-inflammatory strategies within the framework of obesity and diabetes research, where metabolic stress and immune activation intersect.

Advanced Applications and Comparative Advantages

Leptin (116-130), amide, mouse stands out among metabolic peptides for its defined sequence and robust solubility profile. Its utility is exemplified in studies investigating energy homeostasis regulation, where it enables precise titration and time-course analysis of adipocyte signaling. Compared to full-length leptin, the 116-130 fragment offers enhanced specificity for dissecting downstream signaling events, reducing confounding effects from non-receptor mediated interactions.

In comparative workflows, this peptide fragment complements tools used in immunometabolic research. For instance, studies beyond metabolism demonstrate its value in probing the interface between adipose signaling and immune cell function, particularly within models of chronic inflammation and metabolic syndrome. By enabling rapid, reproducible intervention in both in vitro and in vivo settings, Leptin (116-130), amide, mouse accelerates hypothesis testing in obesity and diabetes research, as well as studies of leptin signaling pathway disruption in disease.

Troubleshooting and Optimization Tips

• Solubility Issues: If peptide fails to dissolve completely, increase vortexing time or employ brief sonication (2–3 additional minutes); avoid using ethanol, as solubility is poor in this solvent per product data.
• Batch-to-Batch Consistency: Always verify peptide mass by analytical balance and confirm sequence by mass spectrometry when establishing new lots. Store aliquots desiccated at −20°C to minimize degradation.
• Biological Activity Drop: Prepare working solutions immediately before each use; avoid freeze-thaw cycles and limit solution storage to less than 24 hours at 4°C.
• Assay Sensitivity: When modeling leptin resistance or deficiency, titrate peptide concentrations across a logarithmic range (0.1, 1, 10 μM) to capture both low- and high-sensitivity responses in target tissues or cell lines.
• Multiplexed Endpoints: For advanced immunometabolic phenotyping, pair leptin fragment treatments with multiplex ELISA or flow cytometry panels targeting cytokines (e.g., IL-6, TNF-α), metabolic markers, and immune subsets.

Why This Cross-Domain Matters, Maturity, and Limitations

The intersection of metabolic and inflammatory signaling is increasingly recognized as central to the pathogenesis of both cardiovascular and metabolic diseases. The reference study on SIRT6-AMPK-mediated inflammasome inhibition in atrial remodeling illustrates how strategies developed for metabolic modulation can inform anti-inflammatory and anti-fibrotic research. Employing Leptin (116-130), amide, mouse in this cross-domain context facilitates mechanistic exploration of how adipocyte-derived hormone fragments influence not only energy homeostasis but also immune cell recruitment, tissue remodeling, and chronic inflammation.

However, cross-domain application requires careful validation: while murine models provide robust platforms for initial discovery, translation to human disease contexts demands additional species-specific and pathway-specific controls, as highlighted by the comparative findings in advanced metabolic research.

Future Outlook

The synergy observed between metabolic hormone fragment interventions and inflammasome pathway modulation, as demonstrated in the reference study, points to a promising future for integrated obesity and diabetes research. Leptin (116-130), amide, mouse is poised to accelerate discovery in this space, enabling researchers to dissect molecular crosstalk between metabolism and immunity with unprecedented precision. As new multiplexed models and high-dimensional phenotyping platforms emerge, the role of defined peptide tools like this will only expand.

Continued optimization of assay conditions, including solution handling and endpoint selection, will be critical for translating these insights into actionable preclinical and—eventually—clinical strategies. With reliable supply from APExBIO and an expanding evidence base, Leptin (116-130), amide, mouse is set to remain a foundational component in the toolkit of metabolic and immunometabolic research labs worldwide.